

# ACS Cancer Conference 2025

March 12-14 | Phoenix, AZ

## De-Escalation in Breast Cancer

Kelsey E. Larson MD FACS

University of Kansas Cancer Center

Kansas City, KS




- No disclosures

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.




# Surgeons Leaders in De-Escalation



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Critical Partnership with Breast Imaging



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

Judy C. Boughey, MD<sup>1</sup>; Kari M. Rosenkranz, MD<sup>2</sup>; Karla V. Ballman, PhD<sup>3</sup>; Linda McCall, MS<sup>4</sup>; Bruce G. Haffty, MD<sup>5</sup>; Laurie W. Cuttino, MD<sup>6</sup>; Charlotte D. Kubicky, MD<sup>7</sup>; Huong T. Le-Petross, MD<sup>8</sup>; Armando E. Giuliano, MD<sup>9</sup>; Kimberly J. Van Zee, MS, MD<sup>10</sup>; Kelly K. Hunt, MD<sup>8</sup>; Olwen M. Hahn, MD<sup>11</sup>; Lisa A. Carey, MD<sup>12</sup>; and Ann H. Partridge, MD, MPH<sup>13</sup>

Journal of Clinical Oncology 2023

**5-year LR without MRI 22.6%  
versus 1.7% with MRI (p=0.002)**

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ

## The COMET Randomized Clinical Trial

E. Shelley Hwang, MD, MPH<sup>1</sup>; Terry Hyslop, PhD<sup>2</sup>; Thomas Lynch, PhD<sup>1</sup>; [et al](#)

» [Author Affiliations](#)

*JAMA*. Published online December 12, 2024. doi:10.1001/jama.2024.26698

## Active Monitoring (no surgery) not inferior to Guideline Concordant Care (surgery) at 2 years

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Omission of Axillary Lymph Node Surgical Staging

## SOUND

- JAMA Oncology Sept 2023
- International
- Any age
- <2.0cm tumor
- 1:1 AxillarySx:No Axillary Sx
  - pN+ ALND

## INSEMA

- NEJM Dec 2024
- International
- >50 years old
- <5.0cm tumor
- 1:4 AxillarySx:No Axillary Sx
  - pN+ 1:1 SLN:ALND

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# End Points

## SOUND

- Omission SLN non-inferior DFS at 5 years
- Axillary recurrence low (0.4%) at 5 years

## INSEMA

- Omission SLN non-inferior DFS at 5 years
- Axillary recurrence will continue to be followed (1% versus 0.3% at 5 years)

# Multidisciplinary

## SOUND


- 90% WBI + 10% PBI
- Chemotherapy – provider preference

## INSEMA

- WBI required for all patients
- Chemotherapy – G3, high Ki67, TNBC, HER2+

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.


# New Era in Breast Cancer Care



Grendavora et al. Practical Radiation Oncology. 2019

## Radiation Genomics – LRR and Radiation Benefit, Individualizing Radiation

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.







# Surgeons De-Escalating Breast Cancer Operations



## Surgeons Leaders in Multidisciplinary Breast Cancer De-Escalation Discussion

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# ACS Cancer Conference 2025

March 12-14 | Phoenix, AZ

## De-Escalation in Breast Cancer

Kelsey E. Larson MD FACS  
University of Kansas Cancer Center  
Kansas City, KS